Clinical Trials Market Size & Share 2026-2035

Clinical Trials Market Size

The global clinical trials market accounted for USD 66.3 billion in 2025. The market is expected to grow from USD 70.7 billion in 2026 to USD 144.4 billion in 2035, growing at a CAGR of 8.3% over the analysis period, as per the latest report published by Global Market Insights, Inc.

Rising Chronic Disease Burden Accelerates Demand for Innovative Clinical Trials

The increasing prevalence of chronic diseases and a consequent rise in the demand for novel therapeutics are key factors driving the clinical trials industry.

The growing incidence of chronic conditions such as cancer, diabetes, and cardiovascular diseases has underscored the need for cutting-edge and effective treatments, thereby fuelling the demand for novel therapies and interventions aimed at expanding clinical studies and improving patient outcomes. Chronic diseases are currently the major cause of death among adults in almost all countries, and the toll is projected to increase by 17% over the next 10 years. Globally, approximately one in three adults suffer from multiple chronic conditions. With the rising prevalence of chronic diseases, the demand for effective therapies also increases, prompting pharmaceutical and biotechnology companies to develop new drugs.

Expanding Global Clinical Trial Activity Supports Pharmaceutical Innovation

Between 2022 and 2024, the global clinical trials industry witnessed considerable growth, increasing from USD 54.8 billion in 2022 to USD 62.1 billion in 2024. According to data from ClinicalTrials.gov, as of May 17, 2023, there were 452,604 registered clinical trials globally. Of the total registered studies, 64,838 are actively recruiting participants. This represents a significant increase from over 365,000 registered trials reported in early 2021. The increasing number of clinical trials being conducted worldwide is a major factor driving market growth over the forecast period. Additionally, growing R&D expenditure and an increasing number of drugs in various phases are anticipated to significantly boost clinical trials market growth.

The pharmaceutical and biopharmaceutical industry has one of the highest R&D expenses worldwide. Therefore, this will encourage various biopharma and pharma companies to outsource clinical trial services, thereby augmenting the clinical trials industry growth.  For example, according to recent industry estimates and analysis, global pharmaceutical research and development (R&D) spending has shown significant growth, with figures indicating that expenditure grew from around USD 251 billion in 2022 and is projected to reach approximately USD 350 billion by 2029. Thus, the need for well-established contract research organizations for outsourcing clinical trials is expected to fuel the market growth over the forecast period.

Clinical Trials Enable Advanced Drug Development and Better Patient Outcomes

Clinical trials are large-scale research studies that assess novel tests and treatments and evaluate their effects on human health outcomes. Individuals voluntarily participate in clinical trials to test medical interventions, including drugs, medical devices, and other biological products.

Clinical trials are conductedin four phases and require approval before initiation. Key players involved in the clinical trials market include IQVIA, LabCorp, Syneos Health, ICON plc, and Parexel, which provide services such as clinical trial management, patient recruitment, data analytics, and regulatory support for pharmaceutical and biotechnology companies.

Clinical Trials Market Trends

• The Asia-Pacific region has emerged as the hot spot for performing clinical trials owing to the growing patient population, low cost of conducting studies, the ease of regulatory processes, and the availability of some of the top clinical institutions acting as trial locations.
• For instance, the total clinical trial expenditure in Asia is noted to be around 30%–40% lower than in the EU and the U.S. Hence, the demand for clinical trial services is rising tremendously in emerging economies in Asia.
• For example, between 2017-2021, over 70,000 new clinical trials were registered in the APAC region, the U.S., and the EU5. The APAC region was the largest contributor, with more than 50% of the trials, followed by the U.S. (29%) and the EU5 (17%). Thus, as an increasing number of clinical trials are conducted in the emerging economies of the Asia Pacific region, the clinical trials market is anticipated to witness strong growth.
• Furthermore, increasing R&D investments for the development of innovative drugs are expected to propel the clinical trials industry growth over the forecast period. For example, the top 50 pharmaceutical companies alone are estimated to have spent a total of USD 167 billion in R&D in 2022. R&D spending has increased by almost 60% in the 10 years from 2012 to 2022.
• Moreover, pharmaceutical companies are increasingly adopting R&D outsourcing strategies to maximize their operational performance. Such initiatives offer flexibility and a competitive edge for technological advancement, specialized services with highly skilled professionals, and economic stability to these firms.
• Furthermore, favorable government funding is expected to boost clinical trials industry growth. Several government funding agencies and pharmaceutical companies are increasingly funding clinical trials.
• For example, in the UK, the government sponsors health-related research through organizations such as the Medical Research Council (MRC) and the National Institute for Health Research (NIHR). They also assist in coordinating cancer research on a national level through the NCRI (National Cancer Research Institute). Similarly, the NCI (National Cancer Institute) funds about half of all cancer trials in the U.S. Thus, increasing funding from the government and non-government organizations is supporting the growth of the clinical trials industry.

Clinical Trials Market Analysis

Based on the phase, the clinical trials market is classified into phases I, II, III, and IV. The phase III segment dominated the market, accounting for USD 32.1 billion in 2025.

• Due to their crucial contribution, resource allocation, and confirmatory role in drug development, phase III clinical trials dominate the market. These trials are performed to validate the effectiveness and safety of a drug on a large scale, usually comprising thousands of subjects distributed over many geographical locations or sites.
• Phase III clinical trials aim to determine and confirm the primary evidence collected in the earlier phase trials to confirm the drug is beneficial, safe, and provides effective treatment for the desired indication.

• Before granting a marketing authorization, regulatory bodies such as the FDA and EMA need sufficient phase III evidence, making this the most time-consuming and costly stage of clinical development.
• Moreover, pharmaceutical and biotechnology companies allocate significant resources to phase III trials because of their essential role in establishing a drug's market potential. These trials frequently need extensive infrastructure and partnerships with CROs for proper large-scale processing, thus contributing towards high market growth.

Based on the study design, the clinical trials market is segmented into interventional study, observational study, and expanded access study. The interventional study segment dominated the market in 2025 and is anticipated to grow at a CAGR of 8.5% over the forecast years.

• The interventional study segment is anticipated to witness considerable market growth owing to various advantages associated with this study. The advantages include the elimination of recall bias, as data on exposure are obtained before the disease develops.
• Furthermore, an interventional study is considered to be among the highest level in the hierarchy of evidence, as it provides an enhanced way to measure the efficacy of new interventions.
• The study is likewise noted to be used in most clinical trials, thus resulting in increased demand and high segmental development.
• The study is carried out for the majority of drugs or biologics, followed by clinical procedures and device intervention studies, thereby increasing the demand for such studies.

Based on the therapeutic area, the clinical trials market is segmented into autoimmune disease, oncology, cardiology, infectious disease, dermatology, ophthalmology, neurology, hematology, and other therapeutic areas. The oncology segment dominated the market with 38.3% market share in 2025 and is anticipated to grow at a CAGR of 8.8% over the forecast years.

• The increasing prevalence of cancer has compelled sponsors to focus on developing different therapies and medical devices for better management of cancer, resulting in an increased number of clinical trials and discovery of various drugs for cancer treatment.
• For instance, as per the WHO, over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Such a rising cancer burden increases the demand for new cancer treatments, resulting in high R&D investments to develop cancer drugs. In 2023, the U.S. FDA issued more than 60 oncology approvals, including for 11 first-in-class therapeutics.
• Hence, the growing cancer burden, coupled with rising development and approvals of cancer drugs, will foster the oncology segment growth.
• Moreover, the rising focus of manufacturers on the development of novel cancer diagnostic technologies is anticipated to influence the growth potential of the oncology segment.
• On the other hand, the neurology segment held the second largest market share of 10.3% in 2025, driven by the rising prevalence of neurological disorders such as Alzheimer’s disease, Parkinson’s disease, epilepsy, and multiple sclerosis.
• The growing focus of pharmaceutical and biotechnology companies on developing novel therapies for central nervous system (CNS) disorders, along with the increasing number of clinical trials targeting neurological conditions, has contributed significantly to the segment’s expansion.

Based on the service type, the clinical trials market is bifurcated into outsourcing service and in-house service. The outsourcing service segment dominated the market in 2025 with a market share of 64.4%.

• Pharmaceutical, biotechnology, and medical device companies outsource their trial management to CROs for efficiency and cost savings. The growing complexity in conducting clinical trials has also fuelled the need for outsourcing services.
• In addition, the increasing number of firms conducting global clinical trials makes it essential to utilize CRO services because these firms have established regional hubs around the world for easier and quicker subject enrollment and regulatory approval processes.
• Moreover, pharmaceutical companies are increasingly adopting R&D outsourcing strategies to maximize their operational performance. Outsourcing clinical trials offers flexibility and a competitive edge for technological advancement, specialized services with highly skilled professionals, and economic stability to these firms. This also helps to reduce capital investment associated with huge lab equipment and allows the companies to focus on core expertise.
• Additionally, small to medium biopharma companies tend to lack the resources necessary to perform large-scale trials and, as a result, they are highly dependent on CROs to manage intricate regulatory hurdles and resource distribution.

North America Clinical Trials Market

The North America clinical trials industry dominated the global clinical trials industry in 2025 with a market share of 50.7% and is anticipated to witness growth at a CAGR of 8% over the forecast period.

• North America accounted for the largest share of the global clinical trials industry in 2025, driven by the strong presence of major pharmaceutical and biotechnology companies, well-established research infrastructure, and high R&D investments in drug development.

• The region also benefits from a robust regulatory framework and a large number of clinical research organizations (CROs) that support efficient trial execution.
• Additionally, the growing prevalence of chronic diseases and the increasing number of ongoing clinical studies in the U.S. and Canada further contribute to the region’s market dominance.
• The availability of advanced healthcare facilities, skilled research professionals, and strong funding support from government agencies and private organizations continues to reinforce North America’s leading position in the global clinical trials industry.

The U.S. clinical trials market was valued at USD 26.9 billion and USD 26.4 billion in 2022 and 2023, respectively. The market size reached USD 30.5 billion in 2025, growing from USD 28.6 billion in 2024.

• The significant market growth is attributed to the higher density of pharmaceutical and biotechnology companies across the country. For example, the U.S. pharmaceutical industry is at the forefront of the global pharmaceutical industry, capturing almost half of the global sales revenue of pharmaceuticals.
• Further, increasing complexity in drug development, including precision medicine and biologics, makes it necessary for biopharmaceutical and pharmaceutical companies to invest in clinical trials.
• Further, significant funding from government bodies to promote clinical trials aids in the market growth. For instance, in 2023, clinical research funding by the NIH was around USD 18.9 billion.
• Moreover, increasing focus of pharmaceutical and biotechnology companies on outsourcing clinical trials is expected to fuel the U.S. clinical trials industry growth.

Europe Clinical Trials Market

The Europe clinical trials industry is projected to reach USD 29.4 billion by the end of 2035.

• The increasing market growth is attributed to the growth of the disease burden and increasing awareness for early diagnosis and effective treatment. Furthermore, the presence of key market players in the region contributes to the increasing regional growth.
• Additionally, growing R&D expenditure in the region further exacerbates market growth. For instance, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), EU pharmaceutical R&D spending grew on average 4.4% per year between 2010 and 2022, from USD 31.9 billion to USD 53 billion.
• Also, government funding for drug discovery and related research studies is one of the prominent factors fostering market growth.

Germany clinical trials market is anticipated to witness rapid growth over the forecast years.

• Factors such as an increasing number of clinical trials in the country, high R&D investments, and presence of leading pharma and medical device companies in the country foster market growth.
• As per sources, in 2021, Germany invested over around USD 9 billion in pharmaceutical R&D. This is more than any other European country. Similarly, in 2024, around USD 12.5 billion of expenditure was planned for pharmaceutical product innovation in Germany.
• Such high investments in the pharmaceutical R&D are expected to boost the market growth.

Asia Pacific Clinical Trials Market

The Asia Pacific clinical trials industry is estimated to grow at a robust CAGR of 9% during the forecast period.

• This substantial growth is attributed to the increasing prevalence of chronic diseases such as cardiac diseases, cancer, and diabetes in the region, which is expected to fuel the demand for drugs, thereby accelerating the “clinical trials industry growth.
• Furthermore, the regional disease burden, increase in outsourcing by pharmaceutical and biotechnology companies, and a paradigm shift towards outsourcing have led to positive conditions for the market revenue in the Asia Pacific countries.
• An increasing number of trials being outsourced to countries such as India, China, Japan, and South Korea, as well as ASEAN countries, due to a large patient pool and low cost, is propelling the market in the Asia Pacific.

China clinical trials market is anticipated to experience remarkable growth over the forecast period.

• High market growth in the country can be attributed to the strong government support for healthcare research, expanding pharmaceutical and biotechnology industries, and increasing demand for innovative therapies.
• The country is becoming a leading hub for early-phase trials, especially in oncology, neurology, and rare diseases, owing to the presence of a large number of CROs in the region and lower costs compared to the U.S. and Europe.
• Also, a large patient pool, digital health technologies, and favorable regulatory policies are other factors that drive the market growth.

Latin America Clinical Trials Market

Brazil clinical trials industry is expected to showcase significant growth in the Latin America clinical trials industry.

• With its highly skilled workforce and low operational costs, the country is ideal for clinical trials. Also, its diverse patient population attracts global pharmaceutical and biotechnology enterprises.
• Further, the country's improving regulatory environment, along with a growing focus on research and development, enhances its attractiveness for global pharmaceutical companies.

Middle East & Africa Clinical Trials Market

South Africa clinical trials industry is anticipated to witness rapid growth in the Middle East and Africa clinical trials industry.

• The country's developing healthcare infrastructure, large patient pool, and low operational costs make it attractive for global pharmaceutical companies.
• Additionally, South Africa's favourable regulatory framework and increasing focus on the development of new therapeutics drive the clinical trials industry in the country.

Clinical Trials Market Share

The major players operating in the clinical trials industry include IQVIA, LabCorp, ICON plc, Parexel, and Syneos Health, among others. These top 5 players account for approximately 45% of the market. These market players focus on strategies such as mergers, acquisitions, innovative service development, and launches, and collaboration to generate more revenue and remain competitive. For instance, in September 2021, IQVIA announced a partnership with NRx Pharmaceuticals. This partnership was focused on providing medical information and pharmacovigilance services in preparation for effective regulatory actions and allowing NRx to use IQVIA’s domain experience with COVID-19, data analytics, and assets to assist potential EUA (emergency use authorization) of ZYESAMI.

Other players, such as Veeda, The Emmes Company, Worldwide Clinical Trials, and Medpace, have also undertaken various strategic initiatives including service approval and launch to develop a competitive edge. For instance, in June 2025, Medpace Core Laboratories entered into a strategic partnership with Voximetry, a provider of advanced radiopharmaceutical therapy (RPT) dosimetry software and services, to support radiopharmaceutical clinical trials through integrated dosimetry technology and CRO capabilities. This partnership benefited Medpace by expanding its radiopharmaceutical trial support, strengthening imaging and dosimetry expertise, and enhancing its service offerings for complex oncology studies.

Clinical Trials Market Companies

Prominent players operating in the clinical trials industry include:

• Cadiya (Clinipace)
• Celerio
• Charles River Laboratories
• ClinChoice
• ICON plc
• IQVIA HOLDINGS
• Labcorp Holding (Covance )
• Medpace
• Parexel International Corporation
• Pharmaceutical Product Development (Thermo Fisher Scientific)
• Qserve
• SGS SA
• Syneos Health
• The Emmes Company
• Veeda
• Worldwide Clinical Trials
• Wuxi AppTec Co.

 

• IQVIA

IQVIA is a leading global contract research organization (CRO) that provides advanced clinical trial services, leveraging AI-driven analytics, real-world evidence, and decentralized trial solutions. In October 2021, IQVIA established a 160,000-square-foot lab center for its Q2 Solutions subsidiary. The new center provided an innovative suite of laboratory capabilities, comprising cutting-edge bioanalytical, genomics, vaccine and biomarker laboratories and offers solutions to the industry with several laboratory disciplines under the same facility for biomarker development and delivery. This strategy aimed to improve the company’s overall market presence.

• LabCorp

LabCorp offers comprehensive clinical trial services, including drug development, central laboratory testing, and patient recruitment. In December 2021, Labcorp acquired Toxikon Corporation, a CRO providing nonclinical testing services. The acquisition of Toxikon improves the company’s robust nonclinical development portfolio and helps create a strategic footprint for collaboration with biotechnology and pharmaceutical clients.

Clinical Trials Industry News:

• In November 2025, Caidya invested in additional Medidata Experience solutions, including the Clinical Trial Management System (CTMS) and Clinical Data Studio, as announced by Medidata, a Dassault Systèmes brand and leading clinical trial solutions provider. This investment strengthened Caidya’s operational efficiency, improved data integration and oversight, and supported higher-quality, technology-enabled clinical trial delivery.
• In September 2025, IQVIA launched the AI-enabled Clinical Trial Financial Suite (CTFS), a platform that integrates budgeting, contracting, forecasting, and payment workflows to address inefficiencies caused by fragmented and siloed systems. This initiative benefited IQVIA by streamlining financial operations, enhancing data transparency, and supporting more efficient, end-to-end management of clinical trial costs.
• In June 2025, ClinChoice, a global leader in clinical research, announced its selection to conduct a clinical study on a groundbreaking Chimeric Antigen Receptor T-cell (CAR-T) therapy targeting solid tumors. This study positioned ClinChoice at the forefront of innovative cancer treatments, enhancing its reputation and expanding its portfolio in advanced therapeutic research.
• In March 2025, FibroBiologics partnered with Charles River Laboratories, which provided a master cell bank for its lead candidate CYWC628, a fibroblast-based therapy targeting diabetic foot ulcers affecting millions globally. This collaboration allowed Charles River to expand its CDMO portfolio and strengthen its position in supporting advanced cell therapy clinical programs.
• In March 2025, ICON plc partnered with Mural Health Technologies, Inc., a patient-focused clinical trial technology company, to implement the Mural Link participant management and payments platform. This partnership benefited ICON by improving participant engagement, simplifying payment processes, and reducing administrative burden across clinical trials.
• In January 2025, ICON plc expanded its portfolio of artificial intelligence (AI) tools to improve efficiencies across the clinical trial lifecycle, including study startup, document management, resource forecasting, and metrics reporting. This expansion has enabled ICON to streamline operations, optimize resource allocation, and enhance data-driven decision-making throughout clinical trials.
• In February 2024, Wheeler Bio, Inc., a nimble CDMO, announced a strategic agreement with Charles River Laboratories to offer Wheeler Bio’s Portable CMC platform to Charles River clients. The collaboration aims to accelerate the transition from pre-clinical research directly into human clinical trials, enhancing efficiency and speed for drug development programs. This partnership allowed Charles River to expand its service offerings, attract new clients, and strengthen its position as a full-service CDMO in the pharmaceutical market.

The clinical trials market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 - 2035 for the following segments:

Market, By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

Market, By Study Design

• Interventional study
• Observational study
• Expanded access study

Market, By Therapeutic Area

• Autoimmune disease
• Oncology
• Cardiology
• Infectious disease
• Dermatology
• Ophthalmology
• Neurology
• Hematology
• Other therapeutic areas

Market, By Service Type

• Outsourcing service
• In-house service

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Netherlands
  • Switzerland
  • Russia
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Singapore
  • Malaysia
  • Indonesia
  • Thailand
  • Philippines
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Peru
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE